Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease

Journal of Crohn's and Colitis

Volumn 10, Issue 5, 2016, Pages 507-509

  Papamichael, Konstantinos ^a   Cheifetz, Adam S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

CROHN DISEASE; DRUG BLOOD LEVEL; EDITORIAL; HEALING; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; REMISSION; INTESTINE MUCOSA; TREATMENT OUTCOME;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; TREATMENT OUTCOME;

EID: 84982193743     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw041     Document Type: Editorial

References (20)

1. Levesque BG, Sandborn WJ, Ruel J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 2015;148:37-51.
2. Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17.
3. Papamichael K, Van Stappen T, Vande Casteele N, et al. Infliximab concentration thresholds during induction therapy are associated with shortterm mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015, Dec 8. pii: S1542-3565[15]01613-4. doi: 10.1016/j. cgh.2015.11.014.
4. Zittan E, Kabakchiev B, Milgrom R. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. J Crohns Colitis 2016, Jan 18. pii: jjw014. [Epub ahead of print.]
5. Yarur AJ, Jain A, Hauenstein SI, et al. Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2016, Jan 8. [Epub ahead of print]
6. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF alpha therapy: serum levels of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2015, Oct 29. pii: S1542-3565[15]01492-5. doi: 10.1016/j. cgh.2015.10.025. [Epub ahead of print.]
7. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-4 e2.
8. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015;149:350-5.
9. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016;65:249-55.
10. Barnes EL, Allegretti JR. Are anti-tumor necrosis factor trough levels predictive of mucosal healing in patients with inflammatory bowel disease? A systematic review and meta-analysis. J Clin Gastroenterol 2015, Oct 31. [Epub ahead of print.]
11. Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis 2016. Jan 13. pii: jjw007. [Epub ahead of print.]
12. Ternant D, Karmiris K, Vermeire S, et al. Pharmacokinetics of adalimumab in Crohn's disease. Eur J Clin Pharmacol 2015;71:1155-7.
13. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015;148:1320-9.e3.
14. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 2014;20:1996-2003.
15. Vaughn BP, Cheifetz AS. It is time to treat to trough: staying ahead of the curve in biologic testing. Clin Gastroenterol Hepatol 2015;13:2384.
16. Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1435-42.
17. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis 2015;21:182-97.
18. Hendler SA, Cohen BL, Colombel JF, et al. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis 2015;9:266-75.
19. Brandse JF, Vos LM, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects, and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis 2015;9:973-81.
20. Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFa therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015;261:487-96.